KEI has filed comments on the EC’s Green Paper on Copyright limitations and exceptions. They are on the web here: http://www.keionline.org/index.php?option=com_content&task=view&id=215
UNCTAD head Supachai Panitchpakdi will open up this December 16-19 event in Bangkok. The meeting is funded by the Federal Ministry for Economic Cooperation and Development (BMZ), Germany.
Event: Symposium on Flexibilities in International Intellectual Property Rules and Local Production of Medicines
Date: 16–19 December 2008
Location: Bangkok, Thailand
Venue: Conference Room of Arnoma Hotel
This is an exchange from the ip-health list, that will be updated as the conversation continues, about the impact of the HIF on the generic drug industry developing countries.
—– Original Message —–
From: “James Love”
Cc: “Thomas Pogge” “Aidan Hollis”
Sent: Wednesday, November 19, 2008 2:15 PM
Subject: impact of the HIF on generic industry in developing countries
In an exchange on the i+a listserve, I asked Professor Pogge if the decision to reject open licensing was in part because he was concerned about opposition from certain elements of the pharmaceutical industry. This was his response, shared here with permission:
Aidan Hollis and Thomas Pogge discuss Intellectual Property and the HIF.*
In book on the Health Impact Fund,* Aidan Hollis and Thomas Pogge discuss why voluntary licensing of patents is not required.
In their recent book on the Health Impact Fund,* Aidan Hollis and Thomas Pogge discuss a number of issues. This is what they say about S.2210 (110th Congress), Senator Sanders’ proposal for the Medical Innovation Prize Fund.
Medical Innovation Prize Act of 2007
In their recent book on the Health Impact Fund,* Aidan Hollis and Thomas Pogge discuss a number of issues. This is what they say about compulsory licensing of patents.
The Global Ministerial Forum on Research for Health is meeting in Bamako, Mali from November 17-19, 2008. This Ministerial is organized by the Council on Health Research for Development (COHRED), Global Forum for Health Research, the Republic of Mali, the United Nations Cultural, Scientific and Educational Organization (UNESCO), the World Bank and the World Health Organization (WHO), and coordinated by the Bamako 2008 Secretariat.
KEI will later issue a more detailed comment on the Health Impact Fund. One of the key issues that will be addressed is the way that Hollis and Pogge propose turning the prize fund proposals that are based upon open licensing of patents into something that reinforces the monopoly supply chain.
We understand that one motivation for doing this was to attract support from some large pharmaceutical companies, and the European governments that protect them.